Ascendis Pharma – $136 Million Follow-On

San Diego – November 3, 2016 – Cooley advised the underwriters on Ascendis Pharma’s $136.4 million follow-on offering.

J.P. Morgan, BofA Merrill Lynch and Credit Suisse acted as joint book-running managers for the offering. Wedbush PacGrow acted as a co-manager for the offering.

Ascendis (NASDAQ: ASND) is a biopharmaceutical company applying its TransCon technology to develop a pipeline of sustained release prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Cooley advised Ascendis on its $124 million IPO in 2015.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Charlie Kim Partner, San Diego
Div Gupta Partner, New York
Drew Williamson Partner, San Francisco
Jonie Kondracki Partner, San Francisco
Carlos Ramirez Associate, San Diego
Natasha Leskovsek Partner, Washington, DC
Bill Christiansen Partner, Seattle
Kevin King Partner, Washington, DC
Susan Cooper Philpot Retired Partner, San Francisco
Francis Wheeler Partner, Colorado
Phil Mitchell Partner, New York
Aaron Nudelman Associate, Seattle